Volume 27, Issue 5 pp. 839-847
ORIGINAL ARTICLE

Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials

Houli Luo

Houli Luo

Department of Radiology, Cheng du First People's Hospital, Chengdu, Sichuan, China

Search for more papers by this author
Jian Feng

Jian Feng

Department of Critical Care Medicine, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Yanbiao Zhang

Yanbiao Zhang

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Jie Wang

Jie Wang

Department of Critical Care Medicine, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Gang Xue

Gang Xue

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Xi Huang

Xi Huang

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Shuang You

Shuang You

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Hongfei Dong

Hongfei Dong

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Lingfan Li

Lingfan Li

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Juncheng Li

Juncheng Li

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Hualin Xiao

Hualin Xiao

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Xiang Ai

Xiang Ai

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Xianhui Li

Xianhui Li

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Search for more papers by this author
Bo Huang

Corresponding Author

Bo Huang

Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China

Correspondence

Bo Huang, Department of Burn and Plastic, The General Hospital of Western Theater Command, No. 270 Tianhui Road, Chengdu 610083, China.

Email: [email protected]

Search for more papers by this author
First published: 22 June 2023

Houli Luo, Jian Feng, Yanbiao Zhang, Bo Huang, & Xianhui Li equally contributed to this study.

Abstract

Background

The effects of tenapanor in reducing serum phosphorus in hemodialysis patients with hyperphosphatemia are uncertain and no relevant meta-analysis has been conducted. We performed a meta-analysis of randomized placebo-controlled trials to evaluate the efficacy and safety of tenapanor.

Methods

All randomized controlled trials of tenapanor were searched up to 1 August 2022. The primary endpoint was the change in serum phosphorus level from baseline with tenapanor and placebo. Data on drug-related adverse events (AEs), gastrointestinal AEs and diarrhea were collected to determine the safety of tenapanor.

Results

There were 533 patients throughout five trials that were eligible. Tenapanor significantly lowered blood phosphorus level by 1.79 mg/dl in the mean difference than the placebo. Diarrhea, gastrointestinal AEs, and drug-related AEs were more severe than placebo.

Conclusions

This meta-analysis showed that although drug side effects were common, tenapanor significantly reduced serum phosphorus level in hemodialysis patients.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.